Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of sunitinib malate following hepatic artery embolization for metastatic gastrointestinal neuroendocrine tumors.

Next Previous
Trial Profile

Phase II study of sunitinib malate following hepatic artery embolization for metastatic gastrointestinal neuroendocrine tumors.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal cancer; Liver metastases
  • Focus Therapeutic Use

Most Recent Events

  • 28 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
  • 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 10 Oct 2011 Planned End Date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top